Short Interest in Rafael Holdings, Inc. (NYSE:RFL) Grows By 43.5%

Rafael Holdings, Inc. (NYSE:RFL) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling 55,181 shares, an increase of 43.5% from the February 12th total of 38,452 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 54,408 shares, the days-to-cover ratio is currently 1.0 days. Based on an average daily volume of 54,408 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Rafael

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after purchasing an additional 133,024 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Rafael by 72.9% in the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after buying an additional 190,179 shares in the last quarter. Cable Car Capital LP acquired a new position in Rafael during the second quarter worth $173,000. Citadel Advisors LLC raised its position in Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after acquiring an additional 41,335 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Rafael during the second quarter worth $50,000. Institutional investors own 11.30% of the company’s stock.

Rafael Stock Performance

RFL opened at $1.31 on Monday. Rafael has a 52-week low of $1.12 and a 52-week high of $3.19. The firm has a market capitalization of $67.56 million, a PE ratio of -1.54 and a beta of 0.58. The business’s 50-day simple moving average is $1.28 and its 200 day simple moving average is $1.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Rafael in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rafael presently has a consensus rating of “Sell”.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.